Troponin I

The biomarker of choice to aid the diagnosis of myocardial infarction

  • Request more info about biomarkers
    I would like to know more about Radiometer biomarkers

    Contact Info

    Workplace Details

    By submitting this form, I acknowledge that I have reviewed and understood the data privacy notice.

    All fields must be filled!

  • Download: 5 Elements of Troponin brochure
    Learn more about the 5 elements of troponin testing: including the dynamic release of troponin, timing of sample collection, and the time saved with point-of-care testing. Fill in the form for downloading the brochure.
    Contact Info

    By submitting this form, I acknowledge that I have reviewed and understood the data privacy notice.

    All fields must be filled!

  • Fast Results
  • Risk stratification of patients with ACS
  • No interference from Hemolysis and Biotin*

Troponin tests at the emergency department

When a patient arrives at the emergency department (ED) with chest pain and no or unclear changes on the electrocardiogram (ECG), the ED physician typically orders serial troponin tests [1].

This is to establish if the symptoms are caused by an acute myocardial infarction (AMI) - a heart attack - and to determine the next steps which could either be ruling in a patient for an intervention—or ruling the patient out [1].


*No interference from Biotin up to 2.6 mg/L (2,600 ng/mL).

Troponins are specific markers of cardiac muscle injury

Troponins are proteins of the muscular thin filaments and part of a complex in striated muscle [2].

Cardiac troponins are components of the contractile apparatus of myocardial cells and are expressed almost exclusively in the heart and are the preferred biomarker for the evaluation of myocardial injury. Myocardial injury is defined as being present when blood levels of cTn are increased above the 99th percentile upper reference limit (URL). When the injury is associated with a rising and/or falling pattern of cTn values it indicates myocardial ischaemia and is designated as an acute myocardial infarction [3].

Troponins - an aid in diagnosing myocardial infarction

The diagnosis of myocardial infarction (MI) is based on the detection of a rise and/or fall of cTn values with at least one value above the 99th percentile URL in combination with ECG or imaging changes, ischemic symptoms or other clinical findings [3].

For patients with myocardial infarction, the timing of biomarker release into the blood stream is dependent on the patient's blood flow. Accodringly, measured biomarker concentrations are dependent on how soon after the onset of symptoms, samples are obtained [3].

Troponin tests on the AQT90 FLEX analyzer

The AQT90 FLEX immunoassay analyzer is a benchtop analyzer that brings rapid biomarker assessment capabilities right to the patient’s bedside.

The AQT90 FLEX TnI test is indicated for use as an aid in diagnosing myocardial infarction and in the stratification of patients with acute coronary syndromes.

The AQT90 FLEX analyzer delivers quantitative results on the TnI in less than 19 minutes, accelerating myocardial infarction diagnosis in the ED to support rapid clinical decision making.

Its closed tube system makes troponin testing easy: the operator simply inserts the sample tube into the tube holder in the sample port and the analyzer performs all assay steps automatically. There is no need for sample preparation.

All necessary reagents are included in the test cartridges, which remain stable onboard the analyzer for 17 days ensuring maximum availability and uptime.

Key benefits of Troponin I on the AQT90 FLEX analyzer

  • No blood exposure: closed system
  • No sample or assay preparation
  • No presence of hook effect, carry-over or known interferences at clinically relevant concentrations
  • Interference from heterophilic antibodies are minimized by adding a blocker substance
  • Specimen types: venous whole blood and plasma
  • Sample tubes: Fits most 13 × 75 mm standard tubes

Troponin I assay specifics

Turnaround time:
< 19 min.
CV % (plasma): Within-lab CV% at conc. 0.021 μg/L: 12.9%
99th percentile*: 0.023 μg/L

* This value should only be used as an example. Each laboratory should establish its own decision threshold level.


1. Collet, J, Thiele, K, Barbato, E, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation, European Heart Journal August 2020
2. Welsh P, Preiss D, Sattar N. Utility of High-Sensitivity Troponin T and I: Are They the Same? Expert analysis in American College of Cardiology ( Assessed Nov 2021.
3. Thygesen K, Alpert JS, Jaffe AS, et al., Fourth universal definition of myocardial infarction J Am Coll Cardiol Oct 2018; 72(18):2231-2264

MAPSSS-000754 R2

Cookies are used on this website

Use of cookies
Confirm your account with Radiometer

Please enter a valid email

By submitting your e-mail you agree to the data policy notice
Radiometer is using Microsoft Azure Active Directory to authenticate customer access. If you are already registered you will be taken to Microsoft AD to sign in using your Microsoft AD credentials.
You are already registered
Radiometer is using Microsoft Azure AD to authenticate customer access. If you are already registered you will be taken to AZURE to sign in using your AZURE credentials.
Thank you

We will be sending an e-mail invitation to you shortly to sign in using Microsoft Azure AD.

Radiometer is using Microsoft Azure AD to authenticate customer access.

It seems that your e-mail is not registered with us

Radiometer is using Microsoft Azure AD to authenticate customer access. If your e-mail is not registered with us please click CONTINUE and we will guide you through the sign-in process.
We have previously sent an invitation by e-mail

Please click "Get started" in the e-mail to complete the registration process

Radiometer is using Microsoft Azure AD to authenticate customer access.

We were not able to process your request due to a communication error


It seems this account has not been given access to the portal

Radiometer is using Microsoft AZURE Active Directory to authenticate users

Radiometer uses Azure AD to provide our customers and partners secure access to documents, resources, and other services on our customer portal.

If your organization is already using Azure AD you can use the same credentials to access Radiometer's customer portal.

Key benefits

  • Allow the use of existing Active Directory credentials
  • Single-sign on experience
  • Use same credentials to access future services    

Request access

You will receive an invitation to access our services via e-mail when your request  has been approved.

When you accept the invitation, and your organization is already using AZURE AD, you can use the same credentials to access Radiometer's customer portal. Otherwise, a one-time password will be sent via e-mail to sign in.

Effective Date January 20th, 2023 (last updated January 20th, 2023)



Radiometer values your privacy and the protection of your personal data. This policy (“Policy”) explains how Radiometer its affiliates, subsidiaries or related companies, a full list of which can be located here (together, “Radiometer,”, “our”, “us,” or “we”), collects, uses, shares, transfers and processes data collected from or about you.

Personal Data” is any information that can be used to directly or indirectly identify an individual or that can be reasonably expected to link to an individual. This can include items such as name, address, telephone number, credit card details, email address, ID number, Internet Protocol (“IP”) address of an electronic device used by an individual, or other identifying code (even absent of other identifying information). Statistical and non-identifiable metric data are not considered Personal Data.

The Radiometer subsidiary, affiliate or related company with which you interact is, where applicable, the data controller (or equivalent under applicable law) responsible for the processing of your Personal Data. You can find a list of the relevant legal entities that act as data controllers in Appendix 1 to this Policy.


This Policy describes the types of Personal Data that we may collect, process or disclose about you and how you may govern this processing by exercising applicable legal rights. This Policy applies to both online and offline information collection, including your use of websites or subdomains operated by us, any mobile applications, when we provide products and/or services to you or notify you about prospective items of interest and in other situations where you interact with us in-person, by telephone or by mail where this Policy is posted or referenced.

There may be occasion where you have been provided with a circumstance-specific privacy notice that is separate from this policy, such as privacy notices for specific activities such as Recruitment. To the extent you were provided with a different notice, those notices apply and govern our interactions with you. If you provide Personal Data about parties other than yourself, you are responsible for ensuring their knowledge of how we will process their personal data, and, where applicable, obtaining any necessary consents required in advance.

We are committed to processing Personal Data in accordance with applicable laws. Please note that if you do not wish to provide your Personal Data to us, some products and/or services may become unavailable to you. Your use of any or all these platforms indicates you have been notified of our collection, use, transfer, and disclosure of your information as described in this Policy to the extent permitted by applicable law.

Read more